FDA grants orphan status to Hansa's Guillain-Barré syndrome drug | FDA OKs Osmotica's Parkinson's drug | Pragma to launch anti-inflammatory tablets
February 20, 2018
Bio SmartBrief
SIGN UP ⋅   FORWARD
Today's Top Story
FDA grants orphan status to Hansa's Guillain-Barré syndrome drug
The FDA granted orphan designation to Hansa Medical's IdeS, which is being developed as a treatment for patients with Guillain-Barré syndrome. The company anticipates results later this year from two ongoing studies in highly sensitized patients who do not respond to available desensitization methods.
PharmaBiz (India) (2/19) 
LinkedIn Twitter Facebook Google+ Email
Earn Your Master of Science in Bioinformatics
Rowan University's M.S. in Bioinformatics prepares individuals for careers in the pharmaceutical, biotechnology & biomedical fields. It's designed to address a need for professionals with skills combining biological knowledge and expertise in computational information tools. Learn More
ADVERTISEMENT
Health Care & Policy
FDA OKs Osmotica's Parkinson's drug
Osmotica Pharmaceutical received approval from the FDA for its once-daily Osmolex ER, or amantadine, extended-release tablets as a treatment for patients with Parkinson's disease and drug-induced extrapyramidal reactions in adults.
Reuters (2/19) 
LinkedIn Twitter Facebook Google+ Email
Pragma to launch anti-inflammatory tablets
Pragma Pharmaceuticals is expected to launch Decadron, or dexamethasone, tablets this year. The drug is used to treat inflammation in disorders of organ systems, including dermatological, gastrointestinal, neoplastic, renal and respiratory diseases; allergies; and endocrine, hematologic, neurologic, ophthalmic and rheumatic disorders.
eMPR (2/16) 
LinkedIn Twitter Facebook Google+ Email
Janssen reports positive result of psoriasis drug study
Janssen reported at the 2018 American Academy of Dermatology that patients with moderate to severe plaque psoriasis who were treated with Tremfya, or guselkumab, achieved 90% improvement in their condition at week 28 and maintained that through to week 72 if treatment was continued. Results were from the VOYAGE 2 study, which also demonstrated that 87.6% of the 173 patients who stopped receiving the drug achieved a Psoriasis Area and Severity Index 90 response within six months of restarting retreatment.
PharmaTimes (U.K.) (2/19) 
LinkedIn Twitter Facebook Google+ Email
Gottlieb: FDA probes misuse, abuse of gabapentinoids
Gottlieb: FDA probes misuse, abuse of gabapentinoids
Gottlieb (Zach Gibson/Getty Images)
FDA Commissioner Scott Gottlieb said the agency is taking steps to prevent the potential misuse and abuse of gabapentinoids, which could result in serious adverse events. The agency was alarmed by reports of off-label prescribing of gabapentinoids to treat pain, and as an alternative to opioids.
BioCentury (2/15) 
LinkedIn Twitter Facebook Google+ Email
 
Company & Financial News
Follow-on funding brings in $300M for Amicus
An upsized follow-on funding brought in $300 million for Amicus Therapeutics. Amicus' new-drug application for migalastat, indicated for patients 16 years of age or older with Fabry's disease who have amenable mutations, received priority review status by the FDA.
BioCentury (2/16) 
LinkedIn Twitter Facebook Google+ Email
The Latest From BIO ...
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Use BIOCEO9 to get $200 off the biotech/pharma registration rate. Register today.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
Global Developments
Roche, Genentech's multiple sclerosis therapy approved by Health Canada
Health Canada has approved Roche and Genentech's Ocrevus, or ocrelizumab, as a treatment for adult patients with early-stage primary progressive multiple sclerosis and signs of inflammatory activity. The decision was backed by results of the ORATORIO study, in which the patients who were treated with Ocrevus had a 25% lower risk of disability progression sustained for at least 24 weeks versus placebo use.
Multiple Sclerosis News Today (2/16) 
LinkedIn Twitter Facebook Google+ Email
FDA reviewing Pfizer's experimental lung cancer drug
The FDA, European Medicines Agency and Japan Pharmaceutical and Medical Devices Agency are reviewing Pfizer's new drug application for lorlatinib, an anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer who were previously treated with another ALK TKI. The experimental drug blocks tumor mutations that cause drug resistance and crosses the blood-brain barrier, according to Pfizer.
Specialty Pharmacy Times (2/16) 
LinkedIn Twitter Facebook Google+ Email
Food & Agriculture
Australian, New Zealand food regulators seek input on biotech food rules
Food Standards Australia New Zealand released a consultation paper encouraging views on how it will regulate food products derived from biotechnology. "The review is being conducted to ensure that a broad range of issues has been considered before any decision is made to consider varying the Code," said FSANZ CEO Mark Booth.
FoodNavigator-Asia (2/20) 
LinkedIn Twitter Facebook Google+ Email
Industrial & Environmental
PT Jakarta Tank Terminal to expand total capacity for biofuels, gasoline
The PT Jakarta Tank Terminal's total tank capacity for ethanol, biodiesel and gas will be expanded to more than 350,000 cbm, including an additional eight tanks with a capacity of 100.000 cbm. The expansion will enable compliance with Indonesia's Biofuel Blending Mandate regulations.
Biofuels Digest (2/19) 
LinkedIn Twitter Facebook Google+ Email
News From BIO
Secure document sharing services optimized for life science
ShareVault, a leading provider of highly secure and controlled document sharing solutions and virtual data rooms (VDR), has partnered with BIO to provide member companies with significantly discounted pricing and value-added features. ShareVault's VDR platform is optimized for life science companies of all sizes and flexibly priced so that even small biotech companies can afford and benefit from its technology. The ShareVault solution is intended for due diligence and other applications that require secure sharing of documents with third parties. Learn more and sign up for a free trial.
LinkedIn Twitter Facebook Google+ Email
Learn more about BIO:
Conferences | Join Bio | Media | Issues | Industry
  
  
To conquer fear is the beginning of wisdom.
Bertrand Russell,
philosopher
  
  
The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.
Sign Up
SmartBrief offers 200+ newsletters
Advertise
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Wynn Hansen
P: 202.470.1149
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2018 SmartBrief, Inc.®
Privacy policy |  Legal Information